How should I manage a patient with normal cholesterol and mildly elevated triglycerides (201 mg/dL)?

Management of Triglycerides at 201 mg/dL with Normal Cholesterol

Start with intensive lifestyle modification as first-line therapy, focusing on dietary changes (restricting added sugars to <6% and total fat to 30-35% of daily calories), alcohol restriction, and at least 150 minutes per week of moderate-intensity aerobic exercise—this combination can reduce triglycerides by 20-50% and is the primary treatment for this level of elevation. 1

Risk Stratification First

Before determining pharmacotherapy, assess:

• ASCVD status: Does the patient have established cardiovascular disease?
• Diabetes status: Presence of diabetes with ≥2 additional ASCVD risk factors?
• Other cardiovascular risk factors: Hypertension, smoking, family history, age

This matters because triglycerides at 201 mg/dL fall into the "mild-to-moderate" category (150-499 mg/dL), where treatment decisions depend heavily on overall cardiovascular risk rather than the triglyceride number alone 2, 3.

Lifestyle Interventions (Mandatory First Step)

Dietary Modifications

• Restrict added sugars to <6% of total daily calories (eliminate sugar-sweetened beverages, pastries, desserts, candy)
• Limit total fat to 30-35% of daily calories
• Consume ≥2 servings of fatty fish weekly (salmon, rainbow trout, tuna—8+ ounces total)
• Avoid deep-fried foods and foods high in saturated fats 1

Alcohol

• Restrict or eliminate alcohol consumption—even 1 ounce daily increases triglycerides by 5-10%, and the effect is synergistically worse when combined with high-fat meals 1

Physical Activity

• Minimum 150 minutes per week of moderate-intensity aerobic exercise (or 75 minutes of vigorous-intensity)
• Regular aerobic training reduces triglycerides by approximately 11% (versus only 6% with resistance training alone) 1
• Greatest effect occurs when baseline triglycerides are ≥150 mg/dL 1

Weight Loss

• Target 5-10% body weight reduction if overweight or obese 1

Timeline

• Assess efficacy after 4-12 weeks of lifestyle intervention before escalating therapy 1

Secondary Causes to Address

Evaluate and treat:

• Diabetes mellitus (optimal glycemic control is crucial—uncontrolled diabetes is a major contributor) 4, 5
• Hypothyroidism
• Medications that elevate triglycerides (thiazides, beta-blockers, estrogens, corticosteroids)
• Kidney disease 2

Pharmacotherapy Decision Algorithm

If Patient Has NO Established ASCVD and NO High-Risk Features:

• Continue lifestyle modifications alone
• Recheck triglycerides in 3-6 months
• Studies show that treating triglycerides <200 mg/dL with fibrates does not confer cardiovascular benefit 6

If Patient Has Established ASCVD or Diabetes + ≥2 Additional Risk Factors:

1. Start or optimize statin therapy first (statins are first-line for ASCVD risk reduction and lower triglycerides by 10-15%, up to 25-30% with high-intensity statins) 6, 4, 7

2. If triglycerides remain 135-499 mg/dL on maximally tolerated statin:

   • Consider adding icosapent ethyl 4 grams daily (the only triglyceride-lowering therapy proven to reduce cardiovascular events in the REDUCE-IT trial) 4, 2, 7
   • This applies specifically to patients with established ASCVD or diabetes with elevated cardiovascular risk 4

What NOT to Do:

• Do not use fibrates, niacin, or combined EPA/DHA fish oils for cardiovascular risk reduction—multiple trials have failed to show mortality benefit, and fibrates specifically show no benefit when triglycerides are <200 mg/dL 6, 4
• Do not use statins as monotherapy for severe hypertriglyceridemia (though this patient doesn't have severe elevation) 6

Common Pitfalls

• Jumping to medication without adequate lifestyle trial: The 20-50% reduction achievable with lifestyle changes is substantial and often underutilized 1
• Missing uncontrolled diabetes: Two-thirds of patients with triglycerides ≥150 mg/dL have HbA1c >6.4% 5
• Treating the triglyceride number in isolation: At 201 mg/dL, the primary concern is ASCVD risk, not pancreatitis risk (which becomes relevant at ≥500 mg/dL) 1, 2
• Using over-the-counter fish oil supplements: These contain variable amounts of EPA/DHA (20-50%) and cannot reliably deliver the 4 grams of EPA needed for cardiovascular benefit 6

Monitoring

• Recheck fasting lipid panel in 4-12 weeks after initiating lifestyle changes
• If pharmacotherapy is added, reassess in 6-12 weeks
• Target triglyceride goal: <150 mg/dL 7
• Monitor for statin side effects if initiated (muscle symptoms occur in 5-10% of patients) 6